Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019163 (hepatitis B)
 38,309 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In order to examine the character and phases of injury to the nervous system in HIV infection, 207 persons were observed. In 100, antibodies to the virus and to its separate proteins were discovered by immunofermentation analysis (IFA) reaction and by Western blot test. In 67, first phases of acute inflammation asymptomatic of persistent generalized lymphadenopathy were registered; and in 33, other ailments were found. In this group, which consisted of 74 men and 26 women aged 18-45, 91 were citizens of the Community of Independent States (15 of whom had served in the military) and 9 were citizens of other countries (4 had seen military duty). 75% of cases contracted the infection via sexual transmission. The control group comprised 65 seropositive people at the first screening confirmed by IFA but negative or doubtful by Western blot. Clinical laboratory and special psychological investigations were carried out using a 16-factor personality questionnaire and standard personality analysis methods. Generalized lymphadenopathy was found in 78%, hepatomegaly in 69%, chronic infection of the upper respiratory tract 67%, dermatological pathologies 33%, acute infections 32% (syphilis, hepatitis B), splenomegaly 20%, diarrhea and loss of more than 10% of body mass 11%. There was significant decrease of T-helper cells in 82.8%, in the correlation of the quality of T helper cells and T suppressor cells in 72.4%. In 67 persons who were in the second stage of HIV infection, there was a high frequency of pathological psychological symptoms. According to the personality scale, 60% had schizoid signs, 50% had depression, 40% had psychopathy, 30% had psychasthenia, and 20% had paranoia. When 33 persons in the second and third phase of the disease were measured, schizoid signs increased to 85.7%, depression to 78.6%, psychopathy to 57.1%, psychasthenia to 71.4%, and paranoia to 64.3%. In the first phases of the disease mainly hypochondria, depression, and hysteria predominated, and as the disease progressed, psychopathy, paranoia, psychasthenia, schizoid signs, and mania rose.
 ...
PMID:[HIV infection: the clinical and expert diagnostic aspects]. 817 5

Neuropsychiatric side effects are common with Interferon a 2b. Psychosis and depression have been reported. Several cases of mania have been reported but only few have been associated with treatment for hepatitis B. We report a case of mania with psychotic symptoms in a 21-year-old female diagnosed to have hepatitis-B infection, who was receiving interferon. The report supports the view that dose reductions or pauses during interferon treatment can cause mania. Family history of mood disorder could be a risk factor. Atypical presentations are common in interferon-induced mania. Mania induced by interferon responds well to antimanic drugs. Since the use of interferon is increasing in developing countries, the need for awareness of side effects and management issues are important and these are highlighted.
 ...
PMID:Mania associated with interferon alpha2b treatment. 1749 91

We report the case of a 34-year-old man of African origin, positive for both HIV and hepatitis B virus, who developed symptoms of mania and psychosis while being treated with efavirenz (a non-nucleoside reverse transcriptase inhibitor used in HIV therapy) that required inpatient psychiatric admission and treatment with antipsychotic medication. Our case illustrates multiple predisposing and precipitating factors occurring simultaneously that have been previously implicated individually in the development of neuropsychiatric complications with efavirenz (and other HIV treatments in general). We suggest that patient's commenced on antiretroviral medication should have a screening process for pre-existing mental and medical health problems as well as psychosocial risk factors that might put a patient at risk. In addition with advances in pharmacogenomics we advocate future cytochrome P450 gene variant testing coupled with routine efavirenz plasma concentration monitoring to help ensure maximum treatment benefit and minimal risk of side effects.
 ...
PMID:Neuropsychiatric sequelae in an efavirenz treated patient with hepatitis B. 2212 93